CRSP — CRISPR Therapeutics AG
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1674416 ·
Switzerland
Last close
$50.44
Market Cap
$4.88B
52W High
$78.38
52W Low
$44.12
ADV30
1,617,942
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 10,000,000 | -30,272,000 | -117,269,000 | -91,154,000 | 2,650,770,000 | 291,337,000 | 904,219,000 |
| Mar 2026 | 1,000,000 | -44,949,000 | -130,248,000 | -122,931,000 | 2,725,820,000 | 423,308,000 | 911,264,000 |
| Dec 2025 | 0 | -53,703,000 | -154,764,000 | -130,613,000 | 2,265,243,000 | 347,559,000 | 343,430,000 |
| Sep 2025 | 0 | -57,115,000 | -132,059,000 | -106,441,000 | 2,245,308,000 | 286,497,000 | 329,326,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-369,582,000
Investing CF
$-548,429,000
Financing CF
$1,012,268,000
CapEx
$-4,216,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.76
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,161,636,000
Inventory
—
Receivables
$0
ST Investments
$2,073,015,000
EBIT TTM
$-534,340,000
Pretax Income TTM
$-448,107,000
Interest Exp TTM
—
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,392,000
EBITDA
$-513,174,016
Free Cash Flow
$-215,845,872
Enterprise Value
$3,420,339,968
Total Cash
$2,364,352,000
Total Debt
$783,747,968
Shares Out
96,692,653
Trailing EPS
$-4.71
Book Value
$18.07
ROE
-26.1%
ROA
-14.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -664,571,000 | -581,599,000 | 2,265,243,000 | 343,430,000 | 1,921,813,000 | -345,014,000 |
| Dec 2024 | 35,000,000 | -466,566,000 | -366,252,000 | 2,242,034,000 | 309,954,000 | 1,932,080,000 | -142,774,000 |
| Dec 2023 | 370,000,000 | -222,538,000 | -153,610,000 | 2,229,571,000 | 346,768,000 | 1,882,803,000 | -260,375,000 |
| Dec 2022 | 436,000 | -673,161,000 | -650,175,000 | 2,243,057,000 | 367,578,000 | 1,875,479,000 | -495,741,000 |
TTM Snapshot
Revenues TTM
$4,103,000
NetIncome TTM
$-568,534,000
OpCashFlow TTM
—
Assets (Latest)
$2,725,820,000
Forward EPS
$-3.50
Max Pain — expiry 2026-10-16
max pain strike: $55.00 · spot: $53.39 · call oi: 9,167 · put oi: 6,556
Expected Move to 2026-10-16:
±$3.35
(6.27%) —
implied range
$50.04 –
$56.74
· ATM straddle on $53.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRRK | Scholar Rock Holding Corp | $5.14B | $42.20 | — |
| CGON | CG Oncology, Inc. | $5.61B | $63.26 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.16B | $26.09 | — |
| KOD | Kodiak Sciences Inc. | $5.92B | $94.26 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $6.03B | $13.31 | — |
News headlines (Yahoo Finance, 1h cache)
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
2026-10-09 14:20 · Yahoo
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
2026-10-08 12:30 · Yahoo
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
2026-09-29 12:00 · Yahoo
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
2026-09-29 09:12 · Yahoo
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
2026-09-25 20:50 · Yahoo
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger
2026-09-25 06:09 · Yahoo
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
2026-09-24 16:42 · Yahoo
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-24 13:02 · Yahoo
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 21:49 · Yahoo
Anthropic AI Discovery Gene-Editing Stocks Falling
2026-09-24 12:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.